Every year, 1.27 million people die from antibiotic-resistant infections. A new approach, inspired by nature, turns bacteria's own “weapons” against them: enzymes that break down the protective “armor” of superbugs. The study was published in Applied and Environmental Microbiology.
📖 Read more: DNA Origami: The New Vaccine Against HIV
🦠 The Problem: Biofilm
Bacteria don't live in isolation — they form biofilms, a sticky layer of polysaccharides that protects them from antibiotics and the immune system. Inside this biofilm, bacteria become up to 1,000 times more resistant to drugs. This is the main reason why chronic infections, particularly in the lungs of cystic fibrosis patients, are so difficult to treat.
The bacterium Pseudomonas aeruginosa — on the World Health Organization's critical priority list — produces alginic acid (alginate) as the main component of its biofilm — a polysaccharide that makes up 93-97% of its protective layer.
🔬 One Sugar Destroys Another
The team of Professor Bryan W. Berger at the University of Virginia isolated an enzyme from the bacterium Stenotrophomonas maltophilia — Smlt1473, a polysaccharide lyase. This enzyme breaks down alginic acid through beta-elimination, severing the chemical bonds of the biofilm.
Dual Action
The enzyme Smlt1473 works on two levels. Preventively: it prevents biofilm formation from the start. Therapeutically: it breaks down already formed, mature biofilm. Additionally, it works against acetylated alginate — the form secreted in chronic pulmonary infections — something many other lyases cannot do.
📖 Read more: Lipids Activate STING: New Cancer Defense Mechanism
🧪 Clinical Strain Testing
The team tested the enzyme on 5 different strains of Pseudomonas aeruginosa, including clinical isolates from cystic fibrosis and diabetes patients at the University of Virginia Hospital. In all cases, Smlt1473 successfully inhibited and disrupted the biofilm.
Scanning electron microscope (SEM) images at 50,000x magnification revealed a dramatic reduction of the protective layer in treated samples compared to untreated ones. Essentially, the enzyme “stripped” the bacteria, leaving them exposed to the immune system and antibiotics.
A critical point: the enzyme does not kill bacteria directly — it simply removes their shield. This means it is much harder for bacteria to develop resistance. Tests on human bronchial epithelial cells showed zero toxicity.
💡 Why It Matters
The strategy is remarkably elegant: instead of trying to kill bacteria (where we are increasingly failing), we remove their hiding place. And we do it using the very tools that another bacterium uses in nature.
Given that the WHO warns of a “post-antibiotic era” where simple infections will once again become fatal, approaches like this are not just interesting — they are urgent.